We are live on
!
Find out more
E
Ergoteles Portfolio holdings
AUM
$68.2M
1-Year Est. Return
36.16%
This Fund
S&P 500
This Quarter
Est. Return
+13.32%
1 Year Est. Return
+36.16%
3 Year Est. Return
+76.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.72B
AUM Growth
-$123M
(-4.3%)
Cap. Flow
-$215M
Cap. Flow
% of AUM
-7.9%
Top 10 Holdings %
Top 10 Hldgs %
16.65%
Holding
2,200
New
704
Increased
294
Reduced
353
Closed
800
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Biotechnology ETF
IBB
|
+$85.8M |
| 2 |
Steel Dynamics
STLD
|
+$50.2M |
| 3 |
McKesson
MCK
|
+$43.7M |
| 4 |
STOR
STORE Capital Corporation
STOR
|
+$38.2M |
| 5 |
Arch Capital
ACGL
|
+$26M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CTXS
Citrix Systems Inc
CTXS
|
+$149M |
| 2 |
DRE
Duke Realty Corp.
DRE
|
+$147M |
| 3 |
NLSN
Nielsen Holdings plc
NLSN
|
+$44.3M |
| 4 |
CoStar Group
CSGP
|
+$44.2M |
| 5 |
Chevron
CVX
|
+$43.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 15.28% |
| 2 | Healthcare | 12.35% |
| 3 | Industrials | 12.24% |
| 4 | Technology | 10.34% |
| 5 | Consumer Discretionary | 10.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1301
Candel Therapeutics
CADL
$714M
| $46.7K | ﹤0.01% |
+26,114
| New | +$51.7K |
|
|
GGRP
1302
Glimpse Group
GGRP
$19.7M
| $46.7K | ﹤0.01% |
+15,422
| New | +$67K |
|
1303
AquaBounty Technologies
AQB
$4.54M
| $45.3K | ﹤0.01% |
2,964
-9,689
| -77% | -$132K |
|
1304
Karyopharm Therapeutics
KPTI
$157M
| $45.3K | ﹤0.01% |
+888
| New | +$61.6K |
|
|
TCRR
1305
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $45.1K | ﹤0.01% |
45,150
-65,519
| -59% | -$88.3K |
|
|
AWH
1306
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
| $44.9K | ﹤0.01% |
8,998
-10,226
| -53% | -$55.9K |
|
|
TRML
1307
DELISTED
Tourmaline Bio
TRML
| $44.4K | ﹤0.01% |
+4,352
| New | +$69.9K |
|
|
NAGE
1308
Niagen Bioscience
NAGE
$261M
| $44K | ﹤0.01% |
26,170
-101,041
| -79% | -$160K |
|
1309
Elicio Therapeutics
ELTX
$75.9M
| $42.9K | ﹤0.01% |
5,291
-2,595
| -33% | -$23.6K |
|
|
SURF
1310
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $42.8K | ﹤0.01% |
+52,234
| New | +$51.5K |
|
|
ROVR
1311
DELISTED
Rover Group, Inc. Class A Common Stock
ROVR
| $42.8K | ﹤0.01% |
+11,649
| New | +$49.9K |
|
1312
SelectQuote
SLQT
$133M
| $41.3K | ﹤0.01% |
+61,533
| New | +$40.3K |
|
1313
Curis
CRIS
$9.28M
| $41.2K | ﹤0.01% |
187
-124
| -40% | -$36.4K |
|
1314
Compugen
CGEN
$217M
| $40.9K | ﹤0.01% |
+57,181
| New | +$49.9K |
|
1315
Sky Harbour Group
SKYH
$362M
| $40.9K | ﹤0.01% |
15,360
-2,953
| -16% | -$9.52K |
|
|
CLLS
1316
Cellectis
CLLS
$282M
| $40.7K | ﹤0.01% |
+19,365
| New | +$43.9K |
|
|
INFI
1317
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $38.7K | ﹤0.01% |
69,660
-338,754
| -83% | -$288K |
|
|
CNTB
1318
Connect Biopharma Holdings
CNTB
$130M
| $38.4K | ﹤0.01% |
+44,297
| New | +$36.5K |
|
1319
Bolt Biotherapeutics
BOLT
$7.67M
| $37.1K | ﹤0.01% |
1,425
-2,984
| -68% | -$81.8K |
|
1320
Black Diamond Therapeutics
BDTX
$99.7M
| $36.4K | ﹤0.01% |
20,212
-30,135
| -60% | -$54.3K |
|
1321
Aligos Therapeutics
ALGS
$25.9M
| $34.7K | ﹤0.01% |
1,455
-661
| -31% | -$16.7K |
|
1322
Armata Pharmaceuticals
ARMP
$171M
| $34.6K | ﹤0.01% |
+27,941
| New | +$72.8K |
|
1323
Rapid Micro Biosystems
RPID
$99.6M
| $34.5K | ﹤0.01% |
30,574
-38,859
| -56% | -$94.1K |
|
1324
Satellogic
SATL
$522M
| $34.4K | ﹤0.01% |
11,000
| – | – |
|
1325
Biodesix
BDSX
$227M
| $33.7K | ﹤0.01% |
+733
| New | +$19.9K |
|
Similar funds
ROC
IVMX
AM
JCG
JAMONY
FA
VCM
MCMI
Ergoteles's Q4 2022 Portfolio in Review
As of Q4 2022, Ergoteles held 2,200 positions worth $2.72B, down 4.3% from $2.85B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Ergoteles withdrew a net $215M in Q4 2022, closing 800 positions and reducing 353 holdings. Its most notable exit was Citrix Systems Inc, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Financials at 15% of assets, up from 14% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, Ergoteles opened a new position in McKesson worth $43.9M.
- Ergoteles's largest Q4 2022 buy was McKesson: 117,079 shares worth $43.9M.
- Ergoteles added most to iShares Biotechnology ETF in Q4 2022, an estimated $85.8M increase.
- Ergoteles's biggest Q4 2022 reduction was Alphabet (Google) Class C, cutting an estimated $41.8M.
- Ergoteles fully exited Citrix Systems Inc in Q4 2022, selling an estimated $149M.
- Ergoteles's ten largest holdings make up 17% of its $2.72B portfolio in Q4 2022.
- Ergoteles opened 704 new positions and closed 800 in Q4 2022.
- Ergoteles's portfolio value fell 4.3% quarter-over-quarter to $2.72B.
Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.